This early-phase study tests a new type of immunotherapy called BAFFR-CAR T cells for adults with B-cell acute lymphoblastic leukemia that has come back or not responded to at least two prior treatments. The therapy involves reprogramming a patient's own immune cells to recognize…
Phase: PHASE1 • Sponsor: PeproMene Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC